Loading...
Loading...
Browse all stories on DeepNewz
VisitWill Aliada's technology be integrated into AbbVie's Alzheimer's research by October 2025?
Yes • 50%
No • 50%
AbbVie's official press releases or scientific publications
AbbVie to Acquire J&J-Backed Aliada Therapeutics for $1.4 Billion in Alzheimer's Focus
Oct 28, 2024, 01:52 PM
AbbVie Inc. announced on Monday that it will acquire Aliada Therapeutics, a privately held therapy developer, for $1.4 billion in cash. The acquisition is aimed at strengthening AbbVie's focus on Alzheimer's disease and its neuroscience pipeline. Aliada Therapeutics, a J&J-backed company, is known for its lead compound ALIA-1758 and its novel blood-brain barrier technology, which are expected to enhance AbbVie's capabilities in developing treatments for neurodegenerative diseases. This deal, involving a Phase 1 biotech, marks AbbVie's third acquisition of the year and underscores its commitment to expanding its research and development in the central nervous system (CNS) domain.
View original story
Yes • 50%
No • 50%
Leader • 25%
Top 3 • 25%
Top 5 • 25%
Not in Top 5 • 25%
Successful • 25%
Partially successful • 25%
Unsuccessful • 25%
Trial not completed • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Acquisition of another company • 25%
Launch of a new drug • 25%
Restructuring or cost-cutting measures • 25%
Other strategic move • 25%
Biogen • 25%
Roche • 25%
Pfizer • 25%
Other • 25%
Yes • 50%
No • 50%
1 new acquisition • 25%
4 or more new acquisitions • 25%
3 new acquisitions • 25%
2 new acquisitions • 25%
Q4 2025 • 25%
Q1 2025 • 25%
Q2 2025 • 25%
Q3 2025 • 25%